Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Capital Expenditures (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Capital Expenditures for 4 consecutive years, with -$320000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 122.55% to -$320000.0 in Q4 2025 year-over-year; TTM through Sep 2025 was $1.7 million, a 129.42% increase, with the full-year FY2024 number at $2.2 million, up 868.3% from a year prior.
  • Capital Expenditures was -$320000.0 for Q4 2025 at Day One Biopharmaceuticals, down from $3000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $55.0 million in Q2 2024 to a low of -$54.2 million in Q3 2024.
  • A 4-year average of $186076.9 and a median of $26000.0 in 2022 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 36812.75% in 2024; the steepest drop was 132417.07% in 2024.
  • Day One Biopharmaceuticals' Capital Expenditures stood at $26000.0 in 2022, then plummeted by 69.23% to $8000.0 in 2023, then skyrocketed by 17637.5% to $1.4 million in 2024, then tumbled by 122.55% to -$320000.0 in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Capital Expenditures are -$320000.0 (Q4 2025), $3000.0 (Q2 2025), and $317000.0 (Q1 2025).